2616.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 04:09):

Stats
Today's Volume	650 260
Average Volume	2.58M
Market Cap	1.10B
EPS	HKD0 ( 2024-03-26 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-2.69
ATR14	HKD0.00500 (0.57%)

Volume Correlation

Long: 0.15 (neutral)

Short: -0.66 (moderate negative)

Signal:(46.912) Neutral

CStone Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CStone Pharmaceuticals Correlation - Currency/Commodity

0.50
( weak )

0.50
( neutral )

0.00
( neutral )

0.14
( neutral )

0.00
( neutral )

0.02
( neutral )

CStone Pharmaceuticals Financials

Annual	2023
Revenue:	HKD0
Gross Profit:	HKD0 (0.00 %)
EPS:	HKD0

Q2	2023
Revenue:	HKD130.74M
Gross Profit:	HKD76.72M (58.68 %)
EPS:	HKD-0.0850

Q1	2023
Revenue:	HKD130.74M
Gross Profit:	HKD76.72M (58.68 %)
EPS:	HKD-0.0850

Q4	2022
Revenue:	HKD109.80M
Gross Profit:	HKD54.67M (49.79 %)
EPS:	HKD-0.230

Financial Reports:

No articles found.

CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.